During the past decade, Wuhan Asia Heart Hospital conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 12 clinical trials were completed, i.e. on average, 27.9% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 8 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wuhan Asia Heart Hospital" #1 sponsor was "Wuhan Asia Heart Hospital" with 12 trials, followed by "Actelion" with 4 trials sponsored, "United Therapeutics" with 4 trials sponsored, "Harbin Medical University" with 3 trials sponsored and "Medtronic Cardiac Rhythm and Heart Failure" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 31 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wuhan Asia Heart Hospital" #1 collaborator was "Wuhan Asia Heart Hospital" with 7 trials as a collaborator, "Sichuan Provincial People's Hospital" with 3 trials as a collaborator, "CVie Therapeutics Co. Ltd." with 2 trials as a collaborator, "Guangdong Provincial People's Hospital" with 2 trials as a collaborator and "Peking University First Hospital" with 2 trials as a collaborator. Other collaborators include 58 different institutions and companies that were collaborators in the rest 68 trials.

According to Clinical.Site data, the most researched conditions in "Wuhan Asia Heart Hospital" are "Coronary Artery Disease" (11 trials), "Pulmonary Arterial Hypertension" (7 trials), "Cardiovascular Diseases" (6 trials), "Percutaneous Coronary Intervention" (4 trials) and "Arteriosclerosis" (3 trials). Many other conditions were trialed in "Wuhan Asia Heart Hospital" in a lesser frequency.

Most popular intervention types in "Wuhan Asia Heart Hospital" are "Drug" (23 trials), "Device" (12 trials), "Diagnostic Test" (4 trials), "Behavioral" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Macitentan" (3 trials), "AI-based social software management model" (1 trials), "AMPLATZER™ Cardiac Plug" (1 trials) and "Acarbose" (1 trials). Other intervention names were less common.

The vast majority of trials in "Wuhan Asia Heart Hospital" are 57 trials for "All" genders.

Currently, there are NaN active trials in "Wuhan Asia Heart Hospital". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Wuhan Asia Heart Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Wuhan Asia Heart Hospital, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 17 trials that are defined as “Not Applicable".